HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV)

HC Wainwright reaffirmed their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research note published on Thursday, MarketBeat Ratings reports. The brokerage currently has a $22.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on the company. Piper Sandler Companies reiterated a “buy” rating and set a $30.00 price objective on shares of Acrivon Therapeutics in a research note on Friday, September 6th. BMO Capital Markets reiterated an “outperform” rating and issued a $28.00 price objective (up from $25.00) on shares of Acrivon Therapeutics in a report on Monday, September 16th. LADENBURG THALM/SH SH upgraded Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Monday, September 16th. Finally, JMP Securities reissued a “market outperform” rating and issued a $17.00 target price on shares of Acrivon Therapeutics in a research report on Monday, September 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $23.67.

Acrivon Therapeutics Trading Down 12.1 %

Shares of ACRV stock opened at $6.96 on Thursday. The firm’s fifty day moving average price is $7.78 and its two-hundred day moving average price is $7.78. Acrivon Therapeutics has a 1 year low of $3.19 and a 1 year high of $11.90. The firm has a market capitalization of $215.57 million, a P/E ratio of -2.58 and a beta of 0.66.

Institutional Trading of Acrivon Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. lifted its holdings in Acrivon Therapeutics by 39.2% in the first quarter. American International Group Inc. now owns 6,016 shares of the company’s stock valued at $43,000 after buying an additional 1,695 shares during the period. Rhumbline Advisers increased its stake in shares of Acrivon Therapeutics by 48.9% in the 2nd quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock valued at $94,000 after acquiring an additional 5,320 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in Acrivon Therapeutics during the second quarter worth $58,000. XTX Topco Ltd bought a new position in Acrivon Therapeutics during the second quarter worth $61,000. Finally, Barclays PLC increased its stake in Acrivon Therapeutics by 51.2% in the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after purchasing an additional 11,273 shares in the last quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.